Mindmed's drug R&D is broadening to include mescaline, after approval by a Swiss ethics committee of a new mescaline-based study.
Cybin announces approval to enter its Phase IIa clinical study and defines the scope of the clinical trial.
Novamind is adding a second Client Care Center as it expands its clinic network from four to eight locations.
Over 80% of Canadians are showing symptoms of depression related to the COVID-19 pandemic, with over half of Canadians feeling "down, depressed or hopeless".
Mydecine reports a net loss of CAD$5.2 million for Q1 2021, with cash and cash equivalents of CAD$11.3 million at the end of the quarter.
Scientists have started to investigate whether psilocybin, the primary substance responsible for the psychedelic effects of “magic” mushrooms, could be helpful to those who suffer from migraine headache.
The FDA has approved the use of MDMA by therapists -- to better prepare them to administer MDMA-assisted psychotherapy.